Table 3.
Evaluation data of robustness study.
| Parameter | Sampling interval | EMT | TDF | RPV | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Amount present (mg) |
(%) | %RSD | Amount present (mg) |
(%) | %RSD | Amount present (mg) |
(%) | %RSD | ||
| Wavelength | −1 nm | 200.25 | 100.12 | 0.334 | 297.04 | 99.01 | 0.837 | 24.63 | 98.54 | 0.001 |
| +1 nm | 200.10 | 100.50 | 0.624 | 299.47 | 99.82 | 0.323 | 24.92 | 99.68 | 0.029 | |
|
| ||||||||||
| Mobile phase | −2% | 200.16 | 100.08 | 0.225 | 299.44 | 99.81 | 0.163 | 24.82 | 99.30 | 0.689 |
| +2% | 200.09 | 100.04 | 0.430 | 298.92 | 99.64 | 0.509 | 24.68 | 98.75 | 0.370 | |
|
| ||||||||||
| Flow rate | −0.1 mL | 198.81 | 99.40 | 0.837 | 300.55 | 100.18 | 0.019 | 24.47 | 97.89 | 1.469 |
| +0.1 mL | 196.28 | 98.14 | 3.192 | 298.49 | 99.49 | 0.403 | 24.68 | 98.74 | 0.378 | |
|
| ||||||||||
| pH | −0.05 | 199.7 | 99.85 | 0.74 | 298.7 | 99.56 | 0.21 | 24.59 | 98.36 | 0.22 |
| +0.05 | 199.9 | 99.95 | 0.63 | 300.4 | 100.1 | 0.11 | 24.71 | 98.84 | 0.34 | |